triethylenemelamine has been researched along with Cancer, Second Primary in 2 studies
Triethylenemelamine: Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, JR | 1 |
| Morton, LM | 1 |
| Tucker, MA | 1 |
| Abramson, DH | 1 |
| Seddon, JM | 1 |
| Sampson, JN | 1 |
| Kleinerman, RA | 1 |
| Schlienger, P | 1 |
| Campana, F | 1 |
| Vilcoq, JR | 1 |
| Asselain, B | 1 |
| Dendale, R | 1 |
| Desjardins, L | 1 |
| Dorval, T | 1 |
| Quintana, E | 1 |
| Rodriguez, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retinoblastoma Biomarker Study[NCT00342797] | 2,136 participants (Actual) | Observational | 1993-11-17 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for triethylenemelamine and Cancer, Second Primary
| Article | Year |
|---|---|
Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Long | 2014 |
Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Female; Hu | 2004 |